ABCL Stock Overview
AbCellera Biologics Inc. develops antibody discovery platform.
AbCellera Biologics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$9.08|
|52 Week High||US$55.22|
|52 Week Low||US$9.05|
|1 Month Change||-42.31%|
|3 Month Change||-43.14%|
|1 Year Change||-82.16%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-84.58%|
Recent News & Updates
AbCellera Biologics: Potentially Worth Over $41 Currently, Without COVID Revenues
AbCellera has been pummeled in the market this year, dropping like a stone to the current price of just over $14 a share. I believe this is a huge mistake. AbCellera currently has 131 programs with royalty agreements under contract and that number continues to grow fast. Using a 10% discount rate, I estimate the current value of only the current programs at over $41. This estimate does not include any COVID revenues going forward.
|ABCL||US Life Sciences||US Market|
Return vs Industry: ABCL underperformed the US Life Sciences industry which returned 4.2% over the past year.
Return vs Market: ABCL underperformed the US Market which returned 6.6% over the past year.
|ABCL Average Weekly Movement||10.8%|
|Life Sciences Industry Average Movement||9.0%|
|Market Average Movement||6.6%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: ABCL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: ABCL's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract.
AbCellera Biologics Fundamentals Summary
|ABCL fundamental statistics|
Is ABCL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ABCL income statement (TTM)|
|Cost of Revenue||US$104.25m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.63|
|Net Profit Margin||39.94%|
How did ABCL perform over the long term?See historical performance and comparison
Is AbCellera Biologics undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ABCL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ABCL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ABCL is good value based on its PE Ratio (14.4x) compared to the US Life Sciences industry average (38.3x).
PE vs Market: ABCL is good value based on its PE Ratio (14.4x) compared to the US market (16.7x).
Price to Earnings Growth Ratio
PEG Ratio: ABCL's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: ABCL is good value based on its PB Ratio (2.7x) compared to the US Life Sciences industry average (3.2x).
How is AbCellera Biologics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABCL's earnings are forecast to decline over the next 3 years (-48.3% per year).
Earnings vs Market: ABCL's earnings are forecast to decline over the next 3 years (-48.3% per year).
High Growth Earnings: ABCL's earnings are forecast to decline over the next 3 years.
Revenue vs Market: ABCL's revenue is expected to decline over the next 3 years (-12.2% per year).
High Growth Revenue: ABCL's revenue is forecast to decline over the next 3 years (-12.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ABCL is forecast to be unprofitable in 3 years.
How has AbCellera Biologics performed over the past 5 years?
Last years revenue growth
Earnings and Revenue History
Quality Earnings: ABCL has high quality earnings.
Growing Profit Margin: ABCL became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ABCL's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: ABCL has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ABCL has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (72.2%).
Return on Equity
High ROE: ABCL's Return on Equity (22.1%) is considered high.
How is AbCellera Biologics's financial position?
Financial Position Analysis
Short Term Liabilities: ABCL's short term assets ($803.7M) exceed its short term liabilities ($49.5M).
Long Term Liabilities: ABCL's short term assets ($803.7M) exceed its long term liabilities ($169.8M).
Debt to Equity History and Analysis
Debt Level: ABCL has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ABCL's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: ABCL's debt is well covered by operating cash flow (15491.1%).
Interest Coverage: ABCL's interest payments on its debt are well covered by EBIT (113.4x coverage).
What is AbCellera Biologics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ABCL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ABCL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ABCL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ABCL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ABCL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Carl Hansen (47 yo)
Dr. Carl L. G. Hansen, Ph.D. is a Co-Founder of AbCellera Biologics Inc. and has been its Chief Executive Officer and Director since November 2012 and serves as its Chairperson. Dr. Hansen serves as a Memb...
CEO Compensation Analysis
Compensation vs Market: Carl's total compensation ($USD16.96M) is above average for companies of similar size in the US market ($USD5.23M).
Compensation vs Earnings: Carl's compensation has been consistent with company performance over the past year.
Experienced Management: ABCL's management team is considered experienced (2.4 years average tenure).
Experienced Board: ABCL's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ABCL insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.6%.
AbCellera Biologics Inc.'s employee growth, exchange listings and data sources
- Name: AbCellera Biologics Inc.
- Ticker: ABCL
- Exchange: NasdaqGS
- Founded: 2012
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$2.557b
- Shares outstanding: 281.58m
- Website: https://www.abcellera.com
Number of Employees
- AbCellera Biologics Inc.
- 2215 Yukon Street
- British Columbia
- V5Y 0A1
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/21 00:12|
|End of Day Share Price||2022/01/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.